Biolfolate (Folic Acid) Syrup Dosing
For women of childbearing age who could become pregnant, the recommended dose is 400-800 μg (0.4-0.8 mg) of folic acid daily, starting at least 4 weeks before conception and continuing through the first trimester. 1, 2
Standard Dosing by Risk Category
Low-Risk Women (General Population)
- Daily dose: 400-800 μg (0.4-0.8 mg) 3, 1, 2
- Start at least 1 month (preferably 4 weeks) before planned conception
- Continue through first trimester (12 weeks gestation)
- For women with unplanned pregnancies, begin immediately upon pregnancy recognition
High-Risk Women
Daily dose: 4,000 μg (4 mg) 1
High-risk criteria include:
- Personal or family history of neural tube defects
- Previous pregnancy affected by neural tube defect
- Type 1 diabetes mellitus
- Obesity
- Epilepsy with valproic acid or carbamazepine use
- First-, second-, or third-degree relative with neural tube defect
Timing for high-risk women:
- Start 4 mg daily at least 12 weeks before conception
- After 12 weeks gestation, reduce to standard dose of 400 μg (0.4 mg) 1
Important Clinical Considerations
The FDA labeling for Biolfolate specifically contraindicates use in children under 12 years old without consulting a doctor 4, and pregnant/nursing women should consult a healthcare professional before use 4. This appears to be standard precautionary language for the specific formulation.
Common Pitfalls to Avoid
Late initiation: Most women (61%) start supplementation after conception 5, missing the critical periconceptional period when neural tube closure occurs (days 21-28 post-conception)
Inadequate dosing in obesity: Women with elevated BMI have lower plasma folate levels due to chronic inflammation and increased metabolic demands 5. These women require closer monitoring and may benefit from the higher 4 mg dose.
Assuming fortification is sufficient: While food fortification exists, supplementation remains necessary as dietary intake alone typically doesn't achieve protective folate levels 6
Dosing Nuances
The evidence strongly supports that doses between 400-800 μg are equally effective for neural tube defect prevention in low-risk women 3, 1. Higher doses (>800 μg) in the general population don't provide additional benefit for neural tube defect prevention 1, though they remain safe up to 1,000 μg daily 7.
For the 5 mg dose recommended for high-risk women: this is specifically for orofacial cleft defect prevention and neural tube defect recurrence prevention 8, 9.
Special Populations
Low-birth-weight infants: If supplementation is needed, 25 μg/day is adequate 10
Transfusion-dependent thalassemia: 5 mg weekly is sufficient 11